Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E46.98 EPS (ttm)9.96 Insider Own0.50% Shs Outstand105.66M Perf Week0.30%
Market Cap49.45B Forward P/E28.26 EPS next Y16.56 Insider Trans-13.02% Shs Float79.09M Perf Month-10.20%
Income1.15B PEG2.53 EPS next Q3.85 Inst Own71.00% Short Float3.08% Perf Quarter3.99%
Sales5.24B P/S9.44 EPS this Y39.50% Inst Trans0.39% Short Ratio2.77 Perf Half Y26.08%
Book/sh52.07 P/B8.99 EPS next Y11.58% ROA15.50% Target Price493.00 Perf Year13.90%
Cash/sh12.00 P/C39.00 EPS next 5Y18.58% ROE23.90% 52W Range325.35 - 543.55 Perf YTD27.48%
Dividend- P/FCF50.46 EPS past 5Y38.80% ROI18.20% 52W High-13.90% Beta1.67
Dividend %- Quick Ratio3.40 Sales past 5Y61.30% Gross Margin94.20% 52W Low43.84% ATR11.67
Employees5400 Current Ratio3.80 Sales Q/Q21.20% Oper. Margin32.30% RSI (14)39.52 Volatility1.77% 2.47%
OptionableYes Debt/Eq0.13 EPS Q/Q97.80% Profit Margin22.10% Rel Volume0.62 Prev Close464.02
ShortableYes LT Debt/Eq0.13 EarningsAug 03 BMO Payout0.00% Avg Volume879.77K Price467.98
Recom2.30 SMA20-3.31% SMA50-4.71% SMA20013.03% Volume549,647 Change0.85%
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Aug-18-17 09:18AM  Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning Zacks
Aug-17-17 10:36PM  Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy? Motley Fool
06:33PM  Seattle Genetics' Adcetris Granted Priority Review by FDA Zacks
06:26PM  Novo Nordisk's Semaglutide Shows Remarkable Results in Study Zacks
10:05AM  Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Aug-16-17 06:11PM  Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial Zacks
05:44PM  Spectrum (SPPI) Initiates Phase II Study for Cancer Drug Zacks
10:08AM  Biogen: Goldman Has Conviction!
08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
08:04AM  Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review Zacks
Aug-15-17 06:41PM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : August 15, 2017 Capital Cube
07:54AM  3 Stocks That Could Make You Rich Motley Fool
Aug-14-17 01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
09:37AM  Regeneron to abandon drug for common respiratory virus Reuters
09:32AM  Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings? Zacks
09:06AM  Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus PR Newswire
08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Aug-12-17 09:26AM  Edited Transcript of REGN earnings conference call or presentation 3-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
08:05AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Aug-11-17 08:42AM  Forget Teva (TEVA), Buy These 4 Drug Stocks Instead Zacks
08:05AM  IHS Markit Score downgrades Regeneron Pharmaceuticals Inc to 29 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-10-17 10:13AM  Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus Zacks
Aug-09-17 08:46AM  Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data Zacks
08:05AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Aug-08-17 09:30AM  The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP Zacks
Aug-07-17 04:29PM  Top Research Reports for ExxonMobil, MasterCard & Shell Zacks
Aug-04-17 08:01PM  Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings Motley Fool
03:40PM  We're in the business of being really innovative: Regener... CNBC Videos
08:10AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Regeneron Pharmaceuticals, Inc. ACCESSWIRE
Aug-03-17 07:42PM  Regeneron beats Street 2Q forecasts Associated Press
04:43PM  Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View Zacks
04:23PM  The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise Investor's Business Daily
04:06PM  Regeneron beats profit view, to end antibody deal with Sanofi Reuters
12:17PM  Regeneron: Wait, I Thought It Was Good News?!?!
08:46AM  Market Opens Mixed; Tesla Leads Stocks Rallying On Earnings Investor's Business Daily
08:22AM  Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast PR Newswire
08:03AM  Early movers: YUM, DISH, AET, TEVA, REGN, TSLA, FIT, WYN, SQ & more CNBC
07:54AM  Regeneron (REGN) Q2 Earnings Beat Estimates Zacks
06:39AM  Regeneron quarterly profit nearly doubles Reuters
06:30AM  Regeneron Reports Second Quarter 2017 Financial and Operating Results PR Newswire
06:05AM  Investor Network: REGENERON PHARMACEUTICALS INC to Host Earnings Call ACCESSWIRE
Aug-02-17 09:20AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : August 2, 2017 Capital Cube
08:00AM  Earnings Preview: What To Expect From Regeneron Pharmaceuticals On Thursday Forbes
Aug-01-17 04:15PM  Why Sanofi Earnings Spooked Regeneron Shares To A 6-Week Low Investor's Business Daily
04:05PM  American Upgraded, Regeneron Downgraded, Rockwell Collins PT Raised Investor's Business Daily
03:08PM  Regeneron: Time to Sell?
10:38AM  Analysts Recommendations for Regeneron in July 2017 Market Realist
09:09AM  Dupixent Could Substantially Drive Regenerons Growth Market Realist
08:59AM  The Market In 5 Minutes Benzinga
07:40AM  Kevzara Launch Could Boost Regenerons Revenue Growth Market Realist
Jul-31-17 04:11PM  Why Clovis, Regeneron Are Leading A Biotech Deluge Today Investor's Business Daily
03:05PM  Praluent Could Witness Steady Growth in 2017 Market Realist
01:36PM  Eylea Could Continue to Generate High Revenue Market Realist
12:04PM  Sanofi raises outlook but key eczema drug disappoints investors Reuters
12:02PM  How Regeneron Pharmaceuticals Is Expected to Perform in 2017 Market Realist
10:17AM  Why Regeneron is Slumping
09:56AM  J&J arthritis drug sirukumab raises safety concerns -FDA staff Reuters
Jul-29-17 08:08AM  Ignore the Obamacare fight in Congress and buy these 5 health-care stocks MarketWatch
Jul-26-17 03:23PM  Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings? Zacks
Jul-24-17 07:30AM  Featured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R) Accesswire
Jul-21-17 07:32AM  Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis GlobeNewswire
07:30AM  EU follows U.S. in backing Sanofi, Regeneron eczema drug Reuters
07:30AM  Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis PR Newswire
06:19AM  Biotech Leadership Still In Force Investor's Business Daily
Jul-20-17 04:27PM  Stocks End Tightly Mixed; These 4 Drugmakers Prop Nasdaq, S&P 500 Investor's Business Daily
12:01PM  3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research Corporation (LRCX) InvestorPlace
Jul-17-17 02:30PM  'Stars Align' For These Biotechs To Crush Earnings Consensus Investor's Business Daily
Jul-13-17 09:30AM  Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017 PR Newswire
08:30AM  Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Jul-07-17 01:58PM  Is Amgen Making a Mistake?
Jul-05-17 01:54PM  Bright spots in biotech CNBC Videos
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
09:44AM  Roche (RHHBY) Launches Cobas Test for Bacterial Infections Zacks
Jun-30-17 09:00PM  Beauty of Weakness; Uncertainty Remains: Rev Shark's Best Blog
04:05PM  Nike, Micron, Regeneron Get Price Target Hikes; Walgreens Is A Buy Investor's Business Daily
10:46AM  Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label Zacks
10:02AM  Acorda Files NDA for Parkinson's Disease Candidate Inbrija Zacks
09:30AM featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group Zacks
09:25AM  Can Regeneron Hit $540?
Jun-29-17 10:25AM  Sarepta Appoints Ex-Allergan Executive as CEO and President Zacks
09:59AM  Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy Zacks
08:40AM  Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod Zacks
08:15AM  Corporate News Blog - Regeneron and Sanofi Announced Kevzara Approval by the European Commission Accesswire
Jun-28-17 01:20PM  Neothetics' Fat Reduction Candidate Fails in Phase II Study Zacks
10:30AM  Esperion's Combo Cholesterol Candidate Enters Phase III Zacks
08:24AM  Teva/Xenon Nerve Pain Candidate Fails in Phase II Study Zacks
08:15AM  Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1% Zacks
Jun-27-17 04:13PM  Dow Component Merck Fails To Impress With Cholesterol-Busting Drug Investor's Business Daily
02:20PM  Regeneron Pharmaceuticals Has a Powerful Base Pattern But Looks Extended
12:41PM  5 Biomedical Stocks That Are Expected To Surge Zacks
11:38AM  Agios/Celgene's Leukemia Candidate Positive in Phase I/II Zacks
09:51AM  Regeneron: The More the Merrier?
09:37AM  Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU Zacks
09:22AM  Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion Zacks
08:50AM  Conatus's PSC Candidate Gets Orphan Designation in the U.S. Zacks
07:02AM  Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race? Motley Fool
01:02AM  Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union GlobeNewswire
01:00AM  Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union PR Newswire
Jun-26-17 01:27PM  Is It Time To Step To The Sidelines On Regeneron? Benzinga
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM